4.85

4.34% -0.22

After Hours: 4.85

Foghorn Therapeutics Inc (FHTX)

Overview News Price History Option Chain Financials Why FHTX Down? Discussions Forecast

Foghorn Therapeutics Inc stock is traded at $4.85, with a volume of 122.07K. It is down -4.34% in the last 24 hours and up +18.87% over the past month. Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Previous Close:

$5.07

Open:

$5.03

24h Volume:

122.07K

Relative Volume:

0.52

Market Cap:

$284.76M

Revenue:

$30.91M

Net Income/Loss:

$-74.28M

P/E Ratio:

-3.981

EPS:

-1.2183

Net Cash Flow:

$-86.15M

1W Performance:

-6.55%

1M Performance:

+18.87%

6M Performance:

-17.52%

1Y Performance:

-21.65%

1-Day Range:

$4.76

$5.0834

1-Week Range:

$4.76

$5.39

52-Week Range:

$3.27

$6.95

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name

Foghorn Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

617-586-3100

Address

500 TECHNOLOGY SQUARE, CAMBRIDGE

Employee

106

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

FHTX's Discussions on Twitter

Compare FHTX vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FHTX Foghorn Therapeutics Inc	4.85	284.76M	30.91M	-74.28M	-86.15M	-1.2183
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Resumed	Jefferies	Buy
Dec-18-25	Initiated	BTIG Research	Buy
Nov-07-25	Initiated	Guggenheim	Buy
Sep-17-25	Resumed	B. Riley Securities	Buy
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform
Jan-30-25	Initiated	B. Riley Securities	Buy
Sep-03-24	Initiated	Jefferies	Buy
Aug-19-24	Initiated	Evercore ISI	Outperform
Mar-28-23	Initiated	BofA Securities	Buy
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Nov-22-21	Initiated	H.C. Wainwright	Buy
Nov-17-20	Initiated	Cowen	Outperform
Nov-17-20	Initiated	Goldman	Buy
Nov-17-20	Initiated	Morgan Stanley	Overweight
Nov-17-20	Initiated	Wedbush	Outperform

View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

Jul 25, 2026

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance

Jul 03, 2026

Jul 02, 2026

We're Keeping An Eye On Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Rate - Moomoo

Jul 02, 2026

Jul 01, 2026

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - Investing News Network

Jul 01, 2026

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - GlobeNewswire Inc.

Jul 01, 2026

Jun 29, 2026

Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Foghorn Therapeutics (FHTX) Rises 4.71% as Biotech Stock Tests Key Resistance at $4.43Daily Profile - dars.gov.et

Jun 28, 2026

Jun 26, 2026

Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings - Barchart.com

Jun 26, 2026

Foghorn Therapeutics, Inc. Actuals & Estimates (NASDAQ:FHTX) - TradingView

Jun 26, 2026

Jun 25, 2026

Form 4 Foghorn Therapeutics Inc For: 25 June By Investing.com - Investing.com Australia

Jun 25, 2026

FHTX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options - Stock Titan

Jun 25, 2026

Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike - Stock Titan

Jun 25, 2026

Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares - Stock Titan

Jun 25, 2026

Director at Foghorn (NASDAQ: FHTX) receives 28,000 stock options grant - Stock Titan

Jun 25, 2026

Director Michael Mendelsohn gets 28,000 Foghorn (FHTX) stock options at $4.08 - Stock Titan

Jun 25, 2026

Director Ian F. Smith receives 28,000 Foghorn Therapeutics (FHTX) stock options - Stock Titan

Jun 25, 2026

Foghorn Therapeutics (FHTX) director Simba Gill granted 28,000 stock options - Stock Titan

Jun 25, 2026

Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options - Stock Titan

Jun 25, 2026

Director Douglas G. Cole receives 28,000 Foghorn (NASDAQ: FHTX) stock options - Stock Titan

Jun 25, 2026

Foghorn Therapeutics Stockholders Approve Directors and Governance Matters - The Globe and Mail

Jun 25, 2026

Jun 24, 2026

Shareholders at Foghorn Therapeutics (NASDAQ: FHTX) approve pay and auditor - Stock Titan

Jun 24, 2026

Jun 22, 2026

Foghorn Therapeutics (FHTX) Edges Higher as Stock Holds Above Key SupportLow Volatility Picks - dars.gov.et

Jun 22, 2026

Jun 21, 2026